Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration.
Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials.
Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.
Quality at Xceleron is measured by the production of representative, accurate, and precise data delivered on time to our clients. Its assured by having rigorous Quality Control, Quality Assurance, and instrument capacity in Xceleron’s laboratory.
The quality of our data is our number one priority. Our robust sample preparation techniques are the result of 13 years of scientific insights. Xceleron scientists have developed a proprietary method to account for experimental losses due to incomplete extraction or low column recovery. This method is based on the use of a non-radiolabeled analyte as an internal standard. Our team is constantly working on ways to produce high quality data more efficiently.
Our laboratories are GLP and GCP compliant. The company has approximately 150 Standard Operating Procedures covering Study Conduct, Equipment, Operations, Organization, Health and Safety, and Quality Assurance.
Xceleron Webinar 26 March 2015
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.